2005
DOI: 10.1111/j.1365-2249.2005.02803.x
|View full text |Cite
|
Sign up to set email alerts
|

Cannabinoid influence on cytokine profile in multiple sclerosis

Abstract: SummaryCannabinoids have been suggested as possessing immunomodulatory properties, and cannabinoid receptors are present on leucocytes. Clinically, there is some evidence that cannabinoids may be therapeutically useful in treating multiple sclerosis, which is generally believed to be an autoimmune condition. This paper reports data derived from the Cannabinoids in MS (CAMS) study, which was the largest randomized controlled trial yet conducted to evaluate the therapeutic efficacy of cannabinoids. We found no e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
38
2
2

Year Published

2007
2007
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 62 publications
(43 citation statements)
references
References 21 publications
1
38
2
2
Order By: Relevance
“…Thus, as indicated in Table 3, there are reports that such a drug treatment can reduce signs of EAE inflammation in the spinal cord, reduce demyelination, microglial activation, the T-cell population, and the production of proinflammatory cytokines in the spinal cord after TMEV infection and affect leukocyte trafficking by reducing two leukocyte-endothelial interactions (leukocyte rolling and adhesion) that are thought to contribute to the progression of EAE (and of multiple sclerosis) [45,56]. It is noteworthy, however, that when administered repeatedly, neither Δ 9 -THC (Marinol®) nor cannabis extracts have been found to influence serum cytokine levels in multiple sclerosis patients [57,58].…”
Section: Cannabinoid Receptor Agonists and The Management Of Multiplementioning
confidence: 91%
“…Thus, as indicated in Table 3, there are reports that such a drug treatment can reduce signs of EAE inflammation in the spinal cord, reduce demyelination, microglial activation, the T-cell population, and the production of proinflammatory cytokines in the spinal cord after TMEV infection and affect leukocyte trafficking by reducing two leukocyte-endothelial interactions (leukocyte rolling and adhesion) that are thought to contribute to the progression of EAE (and of multiple sclerosis) [45,56]. It is noteworthy, however, that when administered repeatedly, neither Δ 9 -THC (Marinol®) nor cannabis extracts have been found to influence serum cytokine levels in multiple sclerosis patients [57,58].…”
Section: Cannabinoid Receptor Agonists and The Management Of Multiplementioning
confidence: 91%
“…In addition, serum levels of IFN-γ, IL-10, IL-12, or C-reactive protein in MS patients have not been reported to have any influence on the development of the disease [85]. Nevertheless, a study by Arevalo-Martin et al [86] The potential use of cannabinoids in the treatment of MS also involves the reduced synthesis and secretion of IL-17 by THC and CBD, thereby suppressing the Th17 response [87] which is commonly increased in patients with inflammatory autoimmune pathologies such as MS [88].…”
Section: Multiple Sclerosismentioning
confidence: 99%
“…These probably cause significant stress-responses that are known to be immunosuppressive in EAE (Bolton et al 1997). Importantly, there is no solid data to suggest that doses of medical cannabis cause significant immunosuppressive effects in MS, following analysis of peripheral immune responses (Killestein et al 2003;Katona et al 2005;Sexton et al 2014 (Pryce et al2003;Croxford et al 2008;Webb et al 2008;Hasseldam and Johansen 2010;Hernández-Torres et al 2014;BernalChico et al 2015). In EAE, this is seen by a better functional recovery and a reduced accumulation of disability following paralytic attack Baker et al 2011;Al-Izki et al 2014).…”
Section: Lack Of Marked Immunosuppressive Effects Of Cannabinoids In Eaementioning
confidence: 97%